CSI Rome Analysis of ApoB levels in the NHANES population revealed that guideline recommended ApoB targets have limited value in clinicial practice. Lotte Koopal and Gijs Berkelmans discuss these insights with Dr. Seth Shay Martin and Dr. Allan Sniderman.
CSI Rome Robert Horne is a Professor of Behavioural Medicine at University College London, United Kingdom who studies treatment non-adherence. Monique van Kleef discusses with him why this is a particular problem in hypertension, and how this may be improved.
Iron deficiency impairs quality of life and exercise capacity in heart failure patients. The new ESC HF guidelines recommend measuring and treating iron deficiency to help these patients.
CSI Rome Manon Slob and Shahnam Sharif extensively discuss the results of the EMPA-REG OUTCOME study, the first outcomes trial with an SGLT2 inhibitor, with Prof. Silvio Inzucchi, including what the results may mean for the management of diabetes.
Martin Cowie shares the very clear results of the REM-HF study addressing the question whether outcome can be improved in patients with heart failure with an implanted device, if device data are collected remotely on a weekly basis.
ESC 2016 Dr. Ik-Kyuang Jang shares the insights gained from a pilot study that tested a new therapeutic approach in patients with ACS induced by plaque erosion, namely to give drug therapy instead of placing a stent.
CSI ROME Nicolette van der Sande and Monique van Kleef question Wilko Spiering about the interim results of the CALM-FIM study. This was a first-in-man study with a new device (MobiusHD) for patients with treatment resistant hypertension.
CSI ROME Nicole Jaspers and Manon Slob interview Prof. Paul Ridker about the concept of residual risk and how the different forms may be targeted with novel therapeutic strategies to further lower CV risk.
ESC 2016 The PRAGUE-18 study was a direct comparison between the potent P2Y12 inhibitors prasugrel and ticagrelor. While the study was stopped early due to futility, Steen Dalby Kristensen thinks that there is no major difference between the two agents.
CSI ROME Nicolette van der Sande and Monique van Kleef critically discuss the SPRINT trial results with William Cushman and Sverre Kjeldsen. The professors disagree on whether these results should influence new guidelines.
ESC 2016 Dr. Brian Ference (Detroit, MI, VS) shares the results of a long-term Mendelian randomisation study that suggests that even a mild reduction of both LDL-c levels and SBP can dramatically lower CV event risk.
ESC 2016 Prof. Mariell Jessup (Philadelphia, PA, USA) chaired the ESC Hot Line sesion on Heart Failure. She summarises the findings of remote monitoring studies and stem cell trial and touches upon the discussion this raised.